KalshiVérifier la disponibilitéKYC requis2% de fraisDonnées de résolution vérifiéesAssez bien calibréProbabilité implicite actuelle
Before Jan 1, 2032 59%En tête parmi 6 options
Qualité du marché
47 / 100
Faible qualitéVolume 24h
81,9 €
Liquidité
5,7 k €
Liquidité moyenneÉcart
5.0 pt
Spread modéréDonnées du marché
Mis à jour il y a 10 minutes
14 mai 26, 02:00 UTC1 janv. 28, 04:59 UTC
Tendances
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
Will the FDA approve cytisinicline for smoking cessation?
KalshiWill the FDA approve CagriSema?
KalshiWill the FDA approve intismeran autogene (V940/mRNA-4157)?
KalshiWill FDA approve any mRNA vaccine against melanoma before 2028?
Manifold MarketsWill FDA approve any mRNA vaccine against any type of herpes simplex infection before 2028?
Manifold MarketsWill FDA approve any mRNA vaccine against any strain of influenza before 2028?
Manifold MarketsRègles
If the FDA approves midomafetamine / MDMA for PTSD for marketing the named outcome, then the market resolves to Yes.
Règlement via:Food and Drug Administration
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals:
Marchés ouverts
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No+0.4pt97%
- Yes-0.4pt3%
- Volume total
- 15,7 M €
- Volume 24h
- 52,2 k €
KALSHIMeasles cases in 2026?
- Above 4000+2.0pt99%
- Above 300099%
- Above 600061%
+2 résultats de plus
- Volume total
- 870,4 k €
- Volume 24h
- 2,1 k €
POLYMARKETNew pandemic in 2026?
- No-1.0pt93.1%
- Yes+1.0pt6.9%
- Volume total
- 922,5 k €
- Volume 24h
- 1,8 k €
KALSHICyclosporiasis cases reported in the US in 2026?
- Above 18k99%
- Above 6k99%
- Above 10k99%
+12 résultats de plus
- Volume total
- 32,4 k €
- Volume 24h
- 1,3 k €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No97%
- Yes+0.4pt3%
- Volume total
- 1,6 M €
- Volume 24h
- 933,9 €
KALSHIHealthcare AI adoption in September
- Above 43%87%
- Above 43.75%59%
- Above 45%14%
+4 résultats de plus
- Volume total
- 810,1 €
- Volume 24h
- 767 €
- FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
- Measles cases in U.S. in 2026?
- Measles cases in U.S. by September 30?
- What will the average number of measles cases be during Trump's term?
- When will Beam Therapeutics submit a BLA for Risto-cel?
- Will the FDA approve any psychedelic substance for medical use this year?
- Pandemic in 2026?
- How many human screwworm cases will be reported in the United States in 2026?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- Which countries will have an Ebola case in 2026?
- Ebola: new country confirmed before October 1?
Questions fréquentes
- Quelles sont les probabilités actuelles pour Will the FDA approve MDMA for PTSD? ?
- Kalshi cote Before Jan 1, 2032 à 59% au 11 septembre 2026.
- Quand Will the FDA approve MDMA for PTSD? sera-t-il résolu ?
- Will the FDA approve MDMA for PTSD? doit être résolu le 1 janvier 2028.
- Comment Will the FDA approve MDMA for PTSD? est-il réglé ?
- Kalshi règle ce marché comme suit : If the FDA approves midomafetamine / MDMA for PTSD for marketing the named outcome, then the market resolves to Yes.